"The structural complexity and the synthetic challenges facing glycans have historically hampered efforts to study their multifaceted roles and the application of carbohydrates in drug development. However, in very recent years, new synthetic techniques flanked by the growing knowledge about carbohydrate involvement in physiological and pathological states has spurred renewed interest in the chemistry, biology and therapeutic potentialities of carbohydrates. This book offers an overview of key aspects of carbohydrate biology and chemistry that are fundamental for the design of novel therapeutics. The four-part structure of this book introduces these essential components to life, starting from their structure and biological roles and covering analytical methods and synthesis which pave the way for the development of a wide range of therapeutic applications. Leading experts from around the world are brought together to offer their recent research with the ultimate aim of enlightening the reader on the complex yet exciting field of carbohydrate chemistry. Academic and industrial researchers in structural biology, drug discovery and carbohydrate chemistry will find this book an essential guide to the latest research and future potential of medicinal chemistry."-- Provided by publisher.

• Preface Overview and Recent Advances in QSAR Studies-- Rahul P. Gangwal, Mangesh V. Damre, and Abhay T. Sangamwar Software and Web Resources for Computer-Aided Molecular Modeling and Drug Discovery-- Dharmendra Kumar Yadav, Reeta Rai, Ramendra Pratap, and Harpreet Singh The Rm2 Metrics for Validation of QSAR/QSPR Models-- Kunal Roy and Supratik Kar Considering the Molecular Conformational Flexibility in QSAR Studies-- Javier Garcia, Pablo R. Duchowicz, and Eduardo A. Castro Practical Aspects of Building, Validation and Application of 3D-Pharmacophore Models-- Elumalai Pavadai and Kelly Chibale Application of Conceptual Density Functional Theory in Developing QSAR Models and Their Usefulness in the Prediction of Biological Activity and Toxicity of Molecules-- Sudip Pan, Ashutosh Gupta, Debesh R. Roy, Rajesh K. Sharma, Venkatesan Subramanian, Analava Mitra, and Pratim K. Chattaraj Synopsis of Chemometric Applications to Model PPAR Agonism-- Theodosia Vallianatou, George Lambrinidis, and Anna Tsantili-Kakoulidou Antimicrobial and Immunosuppressive Activitites of Cyclopeptides as Targets for Medicinal Chemistry-- Alicia B. Pomilio, Stella M. Battistaand, and Arturo A. Vitale On the Use of Quantitative Structure Activity Relationships (QSAR) and Global Reactivity Descriptors to Study the Biological Activities of Polychlorinated Biphenyls (PCBs)-- Nazmul Islam Applications of Quantitative Structure-Relative Sweetness Relationships in Food Chemistry-- Cristian Rojas, Pablo R. Duchowicz, Reinaldo Pis Diez, and Piercosimo Tripaldi QSAR Studies of 1, 4-Benzodiazepines as CCKA Antagonist-- Sumitra Nain, P. M. Shivakumar, and Sarvesh Paliwal Docking-Based Scoring Parameters Based QSAR Modeling on a Dataset of Bisphenylbenzimidazole as Non-Nucleoside Reverse Transcriptase Inhibitor-- Surendra Kumar and Meena Tiwari Potential Anti-Inflammatory and Anti-Proliferative Agents.-1h-Isochromen-1-Ones and Their Thio Analogues and Their QSAR Studies-- F. Nawaz Khan, Ponnurengam Malliappan Sivakumar, Mukesh Doble, P. Manivel, and Euh Duck Jeong QSAR Studies on Dihydrofolate Reductase Enzyme: From Model to Biological Activity-- Rajesh Rengarajan, Garima Mathur, Anu Sharma, P. M. Shivakumar, and Sumitra Nain Index.
• (source: Nielsen Book Data)9781771881135 20160919

This important new book provides innovative material, including peer-reviewed chapters and survey articles on new applied research and development, in the scientifically important field of QSAR in medicinal chemistry. QSAR is a growing field because available computing power is continuously increasing, QSAR's potential is enormous, limited only by the quantity and quality of the available experimental input, which are also continuously improving. The number of possible structures for the design of new organic compounds is difficult to imagine, and QSAR helps to predict their activities even before synthesis. The book provides a wealth of valuable information and: * Presents an overview of recent developments in QSAR methodologies along with a brief history of QSAR * Covers the available web resource tools and in silico techniques used in virtual screening and drug discovery processes, compiling an extensive review of web resources in the following categories: databases related to chemical compounds, drug targets, and ADME/toxicity prediction; molecular modeling and drug designing; virtual screening; pharmacophore generation; molecular descriptor calculation software; software for quantum mechanics; ligand binding affinities (docking); and software related to ADME/toxicity prediction * Reviews the rm2 as a more stringent measure for the assessment of model predictivity compared to traditional validation metrics, being specifically important since validation is a crucial step in any QSAR study * Presents linear model improvement techniques that take into account the conformation flexibility of the modeled molecules * Summarizes the building processes of four different pharmacophore models: common-feature, 3D-QSAR, protein-, and protein-ligand complexes * Shows the role of different conceptual density functional theory based chemical reactivity descriptors, such as hardness, electrophilicity, net electrophilicity, and philicity in the design of different QSAR/QSPR/QSTR models * Reviews the use of chemometrics in PPAR research highlighting its substantial contribution in identifying essential structural characteristics and understanding the mechanism of action * Presents the structures and QSARs of antimicrobial and immunosuppressive cyclopeptides, discussing the balance of antimicrobial and haemolytic activities for designing new antimicrobial cyclic peptides * Shows the relationship between DFT global descriptors and experimental toxicity of a selected group of polychlorinated biphenyls, exploring the efficacy of three DFT descriptors * Reviews the applications of Quantitative Structure-Relative Sweetness Relationships (QSRSR), showing that the last decade was marked by an increase in the number of studies regarding QSAR applications for both understanding the sweetness mechanism and synthesizing novel sweetener compounds for the food additive industry The wide coverage makes this book an excellent reference for those in chemistry, pharmacology, and medicine as well as for research centers, governmental organizations, pharmaceutical companies, and health and environmental control organizations.
(source: Nielsen Book Data)9781771881135 20160919

• Aims and Objectives
• Materials and Methods
• Development and Validation of High-Throughput Crystallisation and Analysis (HTCAA) Methodology for Physical Form Screening
• Predicting Crystallisability of Organic Molecules Using Statistical Modelling Techniques
• Exploring the Crystal Structure Landscape of Olanzapine
• Exploring the Physical Form Landscape of Clozapine, Amoxapine and Loxapine
• Conclusions and Further Work.

This thesis investigates a range of experimental and computational approaches to the discovery of solid forms. It illustrates an inexpensive, practical and accurate way to predict the crystallizability of organic compounds based on molecular structure alone, while also highlighting the molecular factors that inhibit or promote crystallization. Furthermore, readers will gain a better understanding of the key factors underpinning solid-state structure and diversity. A major part of the thesis highlights experimental work carried out on two structurally very similar compounds, while another main section examines the influence of small changes in structure and substituents on solid-state structure and diversity using computational tools including crystal structure prediction, PIXEL calculations, Xpac, Mercury and statistical modelling tools. In closing, the author presents a fast validated method for solid-state form screening using Raman microscopy on multi-well plates to explore the experimental crystallization space.

• Front Cover; Drug-Like Properties: Concepts, Structure, Design, and Methods from ADME to Toxicity Optimization; Copyright; Dedication; Contents; Preface; Preface to Second Edition; Preface to First Edition; Chapter 1: Introduction; 1.1. Drug-like Properties in Drug Discovery; 1.2. Purpose of This Book; Problems; References; Chapter 2: Benefits of Property Assessment and Good Drug-Like Properties; 2.1. Introduction; 2.2. Discovery Scientists Optimize Many Properties; 2.3. Introduction to the Drug Discovery and Development Process; 2.4. Benefits of Good Drug-like Properties

• 2.4.1. Reduced Development Attrition2.4.2. More Efficient Drug Discovery; 2.4.3. More Efficient Drug Development; 2.4.4. Higher Patient Compliance; 2.4.5. Improved Biological Research in Drug Discovery; 2.4.6. Enabled Partnerships for Drug Development; 2.4.7. Human Modeling and Clinical Planning; 2.4.8. Balance of Properties and Activity; 2.5. Property Profiling in Drug Discovery; 2.6. Drug-like Property Optimization in Drug Discovery; Problems; References; Chapter 3: In Vivo Environments Affect Drug Exposure; 3.1. Introduction; 3.2. Drug Dosing; 3.3. Stomach

• 3.3.1. Gastric Acidic Degradation3.4. Intestinal Environment; 3.4.1. Dissolution Rate; 3.4.2. Solubility; 3.4.3. Permeability; 3.4.4. Intestinal Metabolism; 3.4.5. Intestinal Enzymatic Hydrolysis; 3.4.6. Absorption Enhancement in the Intestine; 3.5. Bloodstream; 3.5.1. Plasma Enzyme Hydrolysis; 3.5.2. Plasma Protein Binding; 3.5.3. Red Blood Cell Binding; 3.6. Liver; 3.6.1. Permeation into and out of Hepatocytes; 3.6.2. Hepatic Metabolism; 3.6.3. Biliary Extraction; 3.7. Kidney; 3.8. Blood-Tissue Barriers; 3.9. Tissue Distribution; 3.9.1. Nonspecific Binding in Tissue

• 3.10. Consequences of Chirality3.11. Overview of in vivo Challenges to Drug Exposure; Problems; References; Chapter 4: Prediction Rules for Rapid Property Profiling from Structure; 4.1. Introduction; 4.2. General Concepts for Prediction Rules; 4.3. Rule of 5; 4.4. Veber Rules; 4.5. Waring Rules; 4.6. Golden Triangle; 4.7. Other Predictive Rules; 4.8. Application of Rules for Compound Assessment; 4.9. Applications of Predictive Rules; Problems; References; Chapter 5: Lipophilicity; 5.1. Lipophilicity Fundamentals; 5.2. Lipophilicity Effects

• 5.3. Lipophilicity Case Studies and Structure Modification5.3.1. Lipophilicity Modification for Biological Activity; 5.3.2. Lipophilicity Modification for Pharmacokinetics; 5.3.3. Lipophilicity Modification for Toxicity; Problems; References; Chapter 6: pKa; 6.1. pKa Fundamentals; 6.2. pKa Effects; 6.2.1. pKa Affects Efficacy; 6.2.2. pKa Affects Pharmacokinetics; 6.2.3. pKa Affects Toxicity; 6.3. pKa Case Studies; 6.3.1. pKa and Activity Examples; 6.3.2. pKa and Pharmacokinetics Examples; 6.4. Structure Modification Strategies for pKa; Problems; References; Chapter 7: Solubility

Of the thousands of novel compounds that a drug discovery project team invents and that bind to the therapeutic target, only a fraction have sufficient ADME (absorption, distribution, metabolism, elimination) properties, and acceptable toxicology properties, to become a drug product that will successfully complete human Phase I clinical trials. Drug-Like Properties: Concepts, Structure Design and Methods from ADME to Toxicity Optimization, Second Edition, provides scientists and students the background and tools to understand, discover, and develop optimal clinical candidates. This valuable resource explores physiochemical properties, including solubility and permeability, before exploring how compounds are absorbed, distributed, and metabolized safely and stably. Review chapters provide context and underscore the importance of key concepts such as pharmacokinetics, toxicity, the blood-brain barrier, diagnosing drug limitations, prodrugs, and formulation. Building on those foundations, this thoroughly updated revision covers a wide variety of current methods for the screening (high throughput), diagnosis (medium throughput) and in-depth (low throughput) analysis of drug properties for process and product improvement. From conducting key assays for interpretation and structural analysis, the reader learns to implement modification methods and improve each ADME property. Through valuable case studies, structure-property relationship descriptions, and structure modification strategies, Drug-Like Properties, Second Edition, offers tools and methods for ADME/Tox scientists through all aspects of drug research, discovery, design, development, and optimization.

Pharmaceutical manufacturing was one of the first industries to recognize the importance of green chemistry, with pioneering work including green chemistry metrics and alternative solvents and reagents. Today, other topical factors also have to be taken into consideration, such as rapidly depleting resources, high energy costs and new legislation.This book addresses current challenges in modern green chemical technologies and sustainability thinking. It encompasses a broad range of topics covered by the CHEM21 project -- Europe's largest public-private partnership project which aims to develop a toolbox of sustainable technologies for green chemical intermediate manufacture. Divided into two sections, the book first gives an overview of the key green chemistry tools, guidance and considerations aimed at developing greener processes, before moving on to look at cutting-edge synthetic methodologies.Featuring innovative research, this book is an invaluable reference for chemists across academia and industry wanting to further their knowledge and understanding of this important topic.

This book presents efficient and practical methods for the synthesis of various functionalized organic molecules from haloalkynes through different reaction processes such as cross-coupling reactions, nucleophilic additions and cycloadditions. It consists of four chapters demonstrating interesting examples of these transformations, and showcasing the synthetic power of haloalkynes for rapid assembly of complex molecular structures. Most of the protocols allow multiple bond-forming events to occur in a single operation, offering opportunities to advance chemical synthesis and address the increasing demands for green and sustainable chemistry. It also presents a wide range of functionalized products, including many synthetically useful conjugated cyclic and acyclic structures that have potential applications in materials science, chemical biology and natural product synthesis. This book is a valuable reference not only for organic chemists, but also for biologists and materials scientists involved in the modern synthesis of organic compounds and materials. Huanfeng Jiang and Wanqing Wu are both Professors at the School of Chemistry and Chemical Engineering, South China University of Technology, China. Chuanle Zhu is a Postdoctoral Fellow at the School of Chemistry and Chemical Engineering, South China University of Technology, China.

• Preface xi Contributors xiii PART I. INFECTIOUS DISEASES 1 Chapter 1. Entecavir (Baraclude): A Carbocyclic Nucleoside for the Treatment of Chronic Hepatitis B 3 1 Background 3 2 Pharmacology 5 3 Structure Activity Relationship (SAR) 6 4 Pharmacokinetics and Drug Metabolism 7 5 Efficacy and Safety 8 6 Syntheses 8 7 References 14 Chapter 2. Telaprevir (Incivek) and Boceprevir (Victrelis): NS3/4A Inhibitors for Treatment for Hepatitis C Virus (HCV) 15 1 Background 16 2 Pharmacology 16 3 Structure Activity Relationship (SAR) 17 4 PK and Drug Metabolism 20 5 Efficacy and Safety 22 6 Synthesis 24 7 Conclusions 38 8 References 39 Chapter 3. Daclatasvir (Daklinza): The First-in-Class HCV NS5A Replication Complex Inhibitor 43 1 Background 43 2 Discovery Medicinal Chemistry 45 3 Mode of Action 48 4 Pharmacokinetics and Drug Metabolism 49 5 Efficacy and Safety 49 6 Syntheses 52 7 References 57 Chapter 4. Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor 61 1 Background 61 2 Pharmacology 63 3 Structure Activity Relationship (SAR) 64 4 Pharmacokinetics and Drug Metabolism 68 5 Efficacy and Safety 69 6 Syntheses 72 7 Summary 76 8 References 76 Chapter 5. Bedaquiline (Sirturo): A Diarylquinoline that Blocks Tuberculosis ATP Synthase for the Treatment of Multi-Drug Resistant Tuberculosis 81 1 Background 81 2 Pharmacology 84 3 Structure Activity Relationship (SAR) 85 4 Pharmacokinetics and Drug Metabolism 86 5 Efficacy and Safety 87 6 Syntheses 88 7 References 96 PART II. CANCER 99 Chapter 6. Enzalutamide (Xtandi): An Androgen Receptor Antagonist for Late-Stage Prostate Cancer 101 1 Background 101 2 Pharmacology 103 3 Structure Activity Relationship (SAR) 104 4 Pharmacokinetics and Drug Metabolism 108 5 Efficacy and Safety 109 6 Synthesis 111 7 Compounds in Development 114 8 References 115 Chapter 7. Crizotinib (Xalkori): The First-in-Class ALK/ROS Inhibitor for Non-small Cell Lung Cancer 119 1 Background: Non-small Cell Lung Cancer (NSCLC) Treatment 119 2 Discovery Medicinal Chemistry Effort: SAR and Lead Optimization of Compound 2 as a c-Met Inhibitor 120 3 ALK and ROS in Non-small Cell Lung Cancer (NSCLC) Treatment 127 4 Preclinical Model Tumor Growth Inhibition Efficacy and Pharmacology 127 5 Human Clinical Trials 128 6 Introduction to the Synthesis and Limitations of the Discovery Route to Crizotinib Analogs 129 7 Process Chemistry: Initial Improvements 131 8 Process Chemistry: Enabling Route to Crizotinib 135 9 Development of the Commercial Process 141 10 Commercial Synthesis of Crizotinib 147 11 References 152 Chapter 8. Ibrutinib (Imbruvica): The First-in-Class Btk Inhibitor for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia 157 1 Background 157 2 Pharmacology 159 3 Structure Activity Relationship (SAR) 159 4 Pharmacokinetics and Drug Metabolism 161 5 Efficacy and Safety 161 6 Syntheses 162 7 References 164 Chapter 9. Palbociclib (Ibrance): The First-in-Class CDK4/6 Inhibitor for Breast Cancer 167 1 Background 167 2 Pharmacology 168 3 Discovery Program 169 4 Preclinical Profile of Palbociclib 175 5 Clinical Profile of Palbociclib 176 6 Early Process Development for Palbociclib 177 7 Commercial Process for Preparation of Palbociclib 192 8 References 193 PART III. CARDIOVASCULAR DISEASES 197 Chapter 10. Ticagrelor (Brilinta) and Dabigatran Etexilate (Pradaxa): P2Y12 Platelet Inhibitors as Anti-coagulants 199 1 Introduction 200 2 Dabigatran Etexilate 200 3 Ticagrelor 207 4 The Future 219 5 References 220 PART IV. CNS DRUGS 223 Chapter 11. Suvorexant (BELSOMRA): The First-in-Class Orexin Antagonist for Insomnia 225 1 Background 225 2 Pharmacology 229 3 Pharmacokinetics and Drug Metabolism 230 4 Efficacy and Safety 231 5 Structure Activity Relationship (SAR) 231 6 Synthesis 233 7 References 239 Chapter 12. Lorcaserin (Belviq): Serotonin 2C Receptor Agonist for the Treatment of Obesity 243 1 Background 243 2 Pharmacology 245 3 Structure Activity Relationship (SAR) 246 4 Pharmacokinetics and Drug Metabolism 248 5 Efficacy and Safety 249 6 Synthesis 250 7 References 253 Chapter 13. Fingolimod (Gilenya): The First Oral Treatment for Multiple Sclerosis 255 1 Background 255 2 Structure Activity Relationship (SAR) 257 3 Pharmacology 259 4 Human Pharmacokinetics and Drug Metabolism 260 5 Efficacy and Safety 261 6 Syntheses 263 7 Summary 268 8 References 269 Chapter 14. Perampanel (Fycompa): AMPA Receptor Antagonist for the Treatment of Seizure 271 1 Background 271 2 Pharmacology 273 3 Structure Activity Relationship (SAR) 274 4 Pharmacokinetics and Drug Metabolism 276 5 Efficacy and Safety 277 6 Syntheses 278 7 References 280 PART V. ANTI-INFLAMMATORY DRUGS 283 Chapter 15. Tofacitinib (Xeljanz): The First-in-Class JAK Inhibitor for the Treatment of Rheumatoid Arthritis 285 1 Background 285 2 Structure Activity Relationships (SAR) 287 3 Safety, Pharmacology and Pharmacokinetics 289 4 Syntheses 290 5 Development of the Commercial Manufacturing Process 292 6 References 300 PART VI. MISCELLANEOUS DRUGS 303 Chapter 16. Ivacaftor (Kalydeco): A CFTR Potentiator for the Treatment of Cystic Fibrosis 305 1 Background 305 2 Pharmacology 306 3 Structure Activity Relationship (SAR) 307 4 Pharmacokinetics and Drug Metabolism 308 5 Efficacy and Safety 310 6 Syntheses 311 7 References 315 Chapter 17. Febuxostat (Uloric): A Xanthine Oxidase Inhibitor for the Treatment of Gout 317 1 Background 317 2 Pharmacology 319 3 Structure Activity Relationship (SAR) 320 4 Pharmacokinetics and Drug Metabolism 321 5 Efficacy and Safety 322 6 Syntheses 323 7 Drug in Development: Lesinurad Sodium 328 8 References 330 Index 331.
• (source: Nielsen Book Data)9781118820056 20160619

This book covers all aspects of the medicinal chemistry of the latest drugs, and the cutting-edge science associated with them. Following the editors 3 successful drug synthesis books, this provides expert analysis of the pros and cons of different synthetic routes and demystifies the process of modern drug discovery for practitioners and researchers. * Summarizes for each drug: respective disease area, important properties and SAR (structure-activity relationship), and chemical synthesis routes / options * Includes case studies in each chapter * Illustrates how chemistry, biology, pharmacokinetics, and a host of disciplines come together to produce successful medicines * Explains the advantages of process synthesis versus the synthetic route for drug discovery.
(source: Nielsen Book Data)9781118820056 20160619

• Nanostructured systems for fluorescence imaging applications.- Luminescent silica nanoparticles for optical imaging.- Gold-based nanomaterials for applications in nanomedicine.- Core-shell polymer nanoparticles for photodynamic therapy of cancer.- Photoactivable surfaces for biomedical applications.- Up-converting nanoparticles for drug delivery.- Quantum dots for biomedical applications.- Engineered nanoconstructs for multimodal phototherapy.
• (source: Nielsen Book Data)9783319229416 20160619

The series Topics in Current Chemistry presents critical reviews of the present and future trends in modern chemical research. The scope of coverage is all areas of chemical science including the interfaces with related disciplines such as biology, medicine and materials science. The goal of each thematic volume is to give the non-specialist reader, whether in academia or industry, a comprehensive insight into an area where new research is emerging which is of interest to a larger scientific audience. Each review within the volume critically surveys one aspect of that topic and places it within the context of the volume as a whole. The most significant developments of the last 5 to 10 years are presented using selected examples to illustrate the principles discussed. The coverage is not intended to be an exhaustive summary of the field or include large quantities of data, but should rather be conceptual, concentrating on the methodological thinking that will allow the non-specialist reader to understand the information presented. Contributions also offer an outlook on potential future developments in the field. Review articles for the individual volumes are invited by the volume editors. Readership: research chemists at universities or in industry, graduate students.
(source: Nielsen Book Data)9783319229416 20160619

• Introduction: Quinoxaline as a Parent Heterocycle
• Synthesis of Quinoxalines
• Synthesis of Pyrrolo[l, 2-a]quinoxalines
• Synthesis of Imidazo[1,5-a]- and Imidazo[1,2-a]quinoxalines
• Synthesis of Quinoxaline Macrocycles
• Rearrangements of Quinoxalin(on)es in the Synthesis of Benzimidazol(on)es
• Appendix.

This book reviews the fundamental aspects of quinoxaline chemistry: synthesis, reactions, mechanisms, structure, properties, and uses. The first four chapters present a survey of the developments in quinoxaline chemistry since the publication of the monograph on "Condensed Pyrazines" by Cheeseman and Cookson in 1979. These chapters give comprehensive coverage of all the methods of the synthesis of quinoxalines and the important quinoxaline-containing ring systems such as thiazolo[3,4-a]-, pyrrolo[1,2-a]-, and imidazo[1,5-a]quinoxalines. Chapter five describes many new methods for the construction of quinoxaline macrocycles, which are important in applications such as optical devices and materials. The final chapter reviews all previously known rearrangements of heterocyclic systems that lead to benzimidazole derivatives. Mamedov critically analyses these transformations to reveal a novel acid-catalyzed rearrangement of quinoxalinones giving 2-heteroarylbenzimidazoles and 1-heteroarylbenzimidazolones in the presence of nucleophilic reactants (MAMEDOV Heterocycle Rearrangement). This book is of interest to researchers in the fields of heterocyclic and synthetic organic chemistry. .

• Solar water splitting using semiconductor photocatalyst powder.- Co-catalysts for water splitting.- CO2 reduction to hydrocarbons.- Biomimetic water oxidation systems.- Plasmon assisted solar energy conversion.- Heterojunctions in composite photocatalysts.- Physical limits of solar energy conversion in the Earth system.- Nanomaterial Catalysts for Water Photoelectrolysis.- Solar water splitting using photoelectrochemical cells.- Principle of natural photosynthesis.-Advanced and in-situ characterization techniques.- Perspectives.
• (source: Nielsen Book Data)9783319230986 20160815

The series Topics in Current Chemistry presents critical reviews of the present and future trends in modern chemical research. The scope of coverage is all areas of chemical science including the interfaces with related disciplines such as biology, medicine and materials science. The goal of each thematic volume is to give the non-specialist reader, whether in academia or industry, a comprehensive insight into an area where new research is emerging which is of interest to a larger scientific audience. Each review within the volume critically surveys one aspect of that topic and places it within the context of the volume as a whole. The most significant developments of the last 5 to 10 years are presented using selected examples to illustrate the principles discussed. The coverage is not intended to be an exhaustive summary of the field or include large quantities of data, but should rather be conceptual, concentrating on the methodological thinking that will allow the non-specialist reader to understand the information presented. Contributions also offer an outlook on potential future developments in the field. Review articles for the individual volumes are invited by the volume editors. Readership: research chemists at universities or in industry, graduate students.
(source: Nielsen Book Data)9783319230986 20160815

• Introduction.- Ring-Opening Reactions of Aminocyclopropanes.- Synthesis and [4+2] Annulation of Aminocyclobutanes.- Conclusions and Outlook.- Experimental Part.
• (source: Nielsen Book Data)9783319230054 20160619

This thesis presents a general approach to accessing nitrogen-substituted hetero- and carbocycles. In short, the annulation reactions developed in the thesis make it possible to access nitrogen-substituted four-, five- and six-membered rings, all essential building blocks for the synthesis of bioactive molecules. Many natural products display a saturated polycyclic core allowing a well-defined arrangement of functional groups in space. As such, they can interact with biological targets with a high degree of affinity and selectivity, surpassing many synthetic drugs. Nevertheless, the efficient synthesis of such complex ring systems poses a challenge for organic chemistry. Through careful tuning of the electronic properties of a nitrogen donor group and a diester acceptor group, the first [3+2] annulation reaction between aminocyclopropanes and enol ethers or carbonyl compounds is now possible. The reaction proceeded under mild catalytic conditions, and the building blocks obtained can be found at the core of bioactive alkaloids, drugs such as Ramipril and biomolecules such as DNA and RNA. Thanks to the dynamic kinetic asymmetric annulation of aminocyclopropanes with enol ethers and aldehydes, access to enantioenriched compounds is also now possible. Lastly, a synthesis of donor-acceptor aminocyclobutanes via [2+2] cycloaddition using a cheap iron catalyst was developed, allowing them to be used in [4+2] annulations to access cyclohexylamines.
(source: Nielsen Book Data)9783319230054 20160619

• Development of a Manufacturing Process for the Formation of a Nucleoside Drug Candidate
• Development of Efficient Routes to Access C-Glycosides as SGLT-2 Inhibitors for the Treatment of Type 2 Diabetes
• Synthetic Routes to Sofosbuvir
• Synthetic Challenges in the Assembly of Macrocyclic HCV NS3/NS4A Protease Inhibitors: The Case of BILN 2061 and Its Analogs
• Recent Progress in the Synthesis of Super-Statins
• Development of Synthetic Routes to Dolutegravir
• Story of Eribulin Mesylate: Development of the Longest Drug Synthesis.

The series Topics in Heterocyclic Chemistry presents critical reviews on present and future trends in the research of heterocyclic compounds. Overall the scope is to cover topics dealing with all areas within heterocyclic chemistry, both experimental and theoretical, of interest to the general heterocyclic chemistry community. The series consists of topic related volumes edited by renowned editors with contributions of experts in the field. All chapters from Topics in Heterocyclic Chemistry are published Online First with an individual DOI. In references, Topics in Heterocyclic Chemistry is abbreviated as Top Heterocycl Chem and cited as a journal.

• Ch. 1. Origin of Chinmedomics
• Ch. 2. Methods and protocols of Chinmedomics
• Ch. 3. Chinmedomics advancing drug discovery and development from Yinchenhao Tang
• Ch. 4. Chinmedomics approach dissects therapeutic properties of ShenQiWan acting on ShenYangXu Syndrome
• Ch. 5. Metabolic profiling and biomarkers analysis of jaundice syndrome
• Ch. 6. Metabolic profiling and biomarkers analysis of GanYu PiXu Syndrome
• Ch. 7. Metabolic profiling and biomarkers of Yinhuang Syndrome and evaluation of Yinchensini Tang
• Ch. 8. Metabolite profiling and biomarkers analysis of jaundice sydrome-related animal models
• Ch. 9. Metabolomic evaluation of hepatoprotective effect of Yinchenhao Tang and its major bioactive constituents
• Ch. 10. Metabolomics and proteomics annotate therapeutic mechanisms of geniposide
• Ch. 11. Metabolic profiling and potential biomarkers of ShenYinXu Syndrome and the therapeutic effect of Liuweidihuang Wan
• Ch. 12. Metabolic profiling of healthy persons treated with Liuweidihuang Wan
• Ch. 13. Metabolic profiling and potential biomarkers analysis of ShenYangXu Syndrome
• Ch. 14. Metabolic evaluation of ShenQiWan nourishing ShenYangXu Syndrome
• Ch. 15. Metabolic profiling and biomarkers analysis of XinQiXu Syndrome
• Ch. 16. Active constituents screening based on correlation analysis between marker metabolites and the absorbed constituents in WenXin formulae
• Ch. 17. Targeted synergism effects of the combined active constituents of Yinchenhao Tang
• Ch. 18. Metabolic profiling and biomarkers of Type 2 Diabetes and the effective evaluation of the Tinaqi Jiangtang capsule
• Ch. 19. Metabolic biomarkers of alcohol liver damage and the intervention effect of Yinchenhao Tang
• Ch. 20. Metabolic profiling and biomarkers analysis of insomnia and the intervention effects of Suanzaoren Decoction and its related active ingredients
• Ch. 21. Metabolic biomarkers of nonbacterial prostatisis and the treatment evaluation of Phellodendri Amurensis cortex and its main components
• Ch. 22. Metabolic profiling provides a system for the understanding of Alzheimer's Disease in rates post-treatment with Kaixin San
• Ch. 23. Metabolic profiles delineate the effect of Shengmai San on Alzheimer's Disease in rats
• Subject Index.

• Cover; Title Page; Copyright Page; Contents; List of Contributors; About the Editor; Preface; Chapter 1
• Origin of Chinmedomics; 1.1
• Introduction; 1.2
• Application and Challenges of TCM; 1.3
• Metabolomics: An Overview; 1.4
• Process of the Serum Pharmacochemistry of TCM; 1.5
• Establishment and Evolution of Chinmedomics; 1.6
• Potential Value of Chinmedomics; 1.7
• Future Perspectives; References; Chapter 2
• Methods and Protocols of Chinmedomics; 2.1
• Introduction; 2.2
• Analytical Technologies; 2.3
• Sampling; 2.4
• Data Extraction and Analysis

• 2.5
• Marker Identification and Validation2.6
• Correlation Analysis between Marker Metabolites and Absorbed Chemical Components; 2.7
• Goals for Chinmedomics; 2.7.1
• Biological Mechanisms of the TCM Syndrome; 2.7.2
• Pharmacological Effects of Formulae; 2.7.3
• Correlation Analysis of Formulae and Syndrome for Effective Substances; 2.8
• Chinmedomics for Yinchenhao Tang: A Case Study; 2.9
• Conclusions; References; Chapter 3
• Chinmedomics Advancing Drug Discovery and Development from Yinchenhao Tang; 3.1
• Introduction; 3.2
• Experimental Detail; 3.2.1
• Chemicals and Materials

• 3.2.2
• Metabolomics Study3.2.2.1
• Animals Handling; 3.2.2.2
• Metabolomics Analysis Platform; 3.2.3
• Constituents Analysis Using Serum Pharmacochemistry; 3.2.3.1
• Animals; 3.2.3.2
• Preparation of YCHT Samples for LC/MS Analysis In Vitro and In Vivo; 3.2.3.3
• Instrumentation and Conditions; 3.2.3.3.1
• Q-TOF/MS analysis; 3.2.3.3.2
• Data Processing; 3.2.4
• Correlation Analysis between Marker Metabolites and Absorbed Constituents; 3.2.5
• Cell Test to Verify the Efficacy of Chemical Components Correlated with Therapeutic Effect; 3.2.5.1
• Chemicals and Reagents

• 3.2.5.2
• Isolation of Hepatocytes3.2.5.3
• Cell Culture and Treatment; 3.2.5.4
• Flow Cytometric Analysis; 3.2.5.5
• Statistical Analyses; 3.3
• Results and Discussions; 3.3.1
• Metabolomics Analysis of Protective Function of YCHT; 3.3.2
• LC/MS Analysis for YCHT Samples In Vitro and In Vivo; 3.3.2.1
• Optimization of MS Conditions; 3.3.2.2
• UPLC-UV-Q-TOF Analysis of YCHT; 3.3.2.3
• UPLC-UV-Q-TOF Analysis of Plasma Sample after Oral YCHT Administration; 3.3.3
• Correlation Analysis between Marker Metabolites and Absorbed Chemical Components

• 3.3.4
• Cell Test to Verify the Therapeutic Efficacy of the Correlated Chemical Components3.4
• Conclusions; Chapter 4
• Chinmedomics Approach Dissects Therapeutic Properties of ShenQiWan Acting on ShenYangXu Syndrome; 4.1
• Introduction; 4.2
• Experimental Detail; 4.2.1
• Chemicals and Materials; 4.2.2
• Metabolomics Study; 4.2.2.1
• Animal Handling; 4.2.2.2
• Sample Collection and Preparation; 4.2.2.3
• UPLC-Q-TOF-HDMS Analysis; 4.2.2.4
• Metabolic Profiling and Metabolite Analysis; 4.2.3
• Constituents Analysis In Vitro and In Vivo; 4.2.3.1
• Animals

• 4.2.3.2
• Preparation of SQW Samples for Analysis

Chinmedomics: The Integration of Serum Pharmacochemistry and Metabolomics to Elucidate the Scientific Value of Traditional Chinese Medicine uses new experimental techniques and research to open doors in drug discovery and development related to traditional Chinese medicine (TCM). This book features a unique approach that combines chemometric analysis with metabolomics studies to illuminate significant changes that have occurred in syndrome states while simultaneously analyzing the efficacy of chemical ingredients in herbal medicines. Chapters provide cutting-edge information on traditional medicine, analytical technology, natural products, metabolomics, bioinformatics and their applications. This book provides a valuable resource for pharmacologists, pharmaceutical scientists, medicinal plant researchers, pharmacognosists and chemists working with TCM and highlights ways to further research and advances in this area in the future. * Presents a practical guide for new practitioners of Chinmedomics with insights on the current use and future development of this method* Each chapter includes an introduction, method, references to the latest literature, possible mechanisms of action and applications* Edited by the leading experts of research related to Chinmedomics.
(source: Nielsen Book Data)9780128031179 20160618

• PREFACE TO THE THIRD EDITION xv 1 INTRODUCTION 1 1.1 Aim of this Book 1 1.2 An Overview of the Drug Discovery to Approval Process 2 1.3 The Pharmaceutical Industry 6 1.4 Economics of Drug Discovery and Development 11 1.5 Trends in Drug Discovery and Development 13 1.6 Case Study #1.1 15 1.7 Case Study #1.2 17 1.8 Summary of Important Points 20 1.9 Review Questions 20 1.10 Brief Answers and Explanations 21 1.11 Further Reading 22 2 DRUG DISCOVERY: TARGETS AND RECEPTORS 23 2.1 Drug Discovery Processes 23 2.2 Medical Needs 24 2.3 Target Identification 26 2.4 Target Validation 34 2.5 Drug Interactions with Targets or Receptors 37 2.6 Enzymes 40 2.7 Receptors and Signal Transduction 43 2.8 Assay Development 52 2.9 Case Study #2.1 52 2.10 Case Study #2.2 53 2.11 Summary of Important Points 57 2.12 Review Questions 58 2.13 Brief Answers and Explanations 58 2.14 Further Reading 59 3 DRUG DISCOVERY: SMALL MOLECULE DRUGS 61 3.1 Introduction 61 3.2 Irrational Approach 62 3.3 Rational Approach 67 3.4 Antisense Approach 85 3.5 RNA Interference Approach 88 3.6 Chiral Drugs 91 3.7 Closing Remarks 92 3.8 Case Study #3.1 94 3.9 Case Study #3.2 96 3.10 Summary of Important Points 98 3.11 Review Questions 99 3.12 Brief Answers and Explanations 99 3.13 Further Reading 100 4 DRUG DISCOVERY: LARGE MOLECULE DRUGS 103 4.1 Introduction 103 4.2 Vaccines 105 4.3 Antibodies 117 4.4 Cytokines 128 4.5 Hormones 134 4.6 Gene Therapy 137 4.7 Stem Cells and Cell Therapy 139 4.8 Case Study #4.1 141 4.9 Case Study #4.2 144 4.10 Summary of Important Points 146 4.11 Review Questions 147 4.12 Brief Answers and Explanations 148 4.13 Further Reading 148 5 DRUG DEVELOPMENT AND PRECLINICAL STUDIES 151 5.1 Introduction 151 5.2 Pharmacodynamics (PD) 154 5.3 Pharmacokinetics (PK) 158 5.4 Toxicology 168 5.5 Animal Tests, In Vitro Assays, and In Silico Methods 172 5.6 Formulations and Delivery Systems 175 5.7 Nanotechnology 183 5.8 Case Study #5.1 184 5.9 Case Study #5.2 185 5.10 Summary of Important Points 187 5.11 Review Questions 188 5.12 Brief Answers and Explanations 188 5.13 Further Reading 189 6 CLINICAL TRIALS 191 6.1 Definition of Clinical Trial 191 6.2 Ethical Considerations 192 6.3 Clinical Trials 195 6.4 Regulatory Requirements for Clinical Trials 204 6.5 Clinical Data Management 215 6.6 Role of Regulatory Authorities 218 6.7 Gene Therapy Clinical Trial 218 6.8 Adaptive Clinical Trial 220 6.9 Meta-Analysis 221 6.10 Case Study #6.1 222 6.11 Case Study #6.2 226 6.12 Summary of Important Points 227 6.13 Review Questions 228 6.14 Brief Answers and Explanations 228 6.15 Further Reading 229 7 REGULATORY AUTHORITIES 231 7.1 Role of Regulatory Authorities 231 7.2 US Food and Drug Administration 233 7.3 European Medicines Agency 236 7.4 Japan s Pharmaceuticals and Medical Devices Agency (PMDA) 238 7.5 China Food and Drug Administration 240 7.6 India s Central Drugs Standard Control Organization 240 7.7 Australia s Therapeutic Goods Administration 241 7.8 Canada s Health Canada 243 7.9 Other Regulatory Authorities 243 7.10 Authorities Other Than Drug Regulatory Agencies 243 7.11 International Conference on Harmonization 244 7.12 World Health Organization 245 7.13 Pharmaceutical Inspection Cooperation Scheme 246 7.14 Case Study # 7.1 246 7.15 Case Study # 7.2 249 7.16 Summary of Important Points 250 7.17 Review Questions 251 7.18 Brief Answers and Explanations 251 7.19 Further Reading 252 8 REGULATORY APPLICATIONS 253 8.1 Introduction 253 8.2 United States 254 8.3 European Union 272 8.4 Japan 280 8.5 China 282 8.6 India 287 8.7 Australia 287 8.8 Canada 287 8.9 Case Study #8.1 290 8.10 Case Study #8.2 292 8.11 Summary of Important Points 294 8.12 Review Questions 299 8.13 Brief Answers and Explanations 299 8.14 Further Reading 300 9 GOOD MANUFACTURING PRACTICE: REGULATORY REQUIREMENTS 301 9.1 Introduction 301 9.2 United States 302 9.3 Europe 308 9.4 International Conference on Harmonization (ICH) 309 9.5 Pharmaceutical Inspection Cooperation Scheme (PIC/S) 311 9.6 Selected Core Elements of GMP 312 9.7 Selected GMP Systems 335 9.8 New cGMP Initiatives 350 9.9 Case Study #9.1 352 9.10 Case Study #9.2 358 9.11 Summary of Important Points 362 9.12 Review Questions 363 9.13 Brief Answers and Explanations 363 9.14 Further Reading 364 10 GOOD MANUFACTURING PRACTICE: DRUG MANUFACTURING 367 10.1 Introduction 367 10.2 GMP Manufacturing 371 10.3 GMP Inspection 372 10.4 Manufacture of Small Molecule APIs (Chemical Synthesis Methods) 379 10.5 Manufacture of Large Molecule APIs (Recombinant DNA Methods) 385 10.6 Finished Dosage Forms 394 10.7 Product Quality Review 398 10.8 Manufacturing Variations 399 10.9 Case Study #10.1 400 10.10 Case Study #10.2 404 10.11 Summary of Important Points 407 10.12 Review Questions 408 10.13 Brief Answers and Explanations 408 10.14 Further Reading 408 11 FUTURE PERSPECTIVES 411 11.1 Past Advances and Future Challenges 411 11.2 Small Molecule Pharmaceutical Drugs 412 11.3 Large Molecule Biopharmaceutical Drugs 414 11.4 Traditional Medicine 414 11.5 Personalized Medicine 419 11.6 Gene Therapy 420 11.7 Cloning and Stem Cells 420 11.8 Old Age Diseases and Aging 423 11.9 Lifestyle Drugs 423 11.10 Performance-Enhancing Drugs 428 11.11 Chemical and Biological Terrorism 428 11.12 Transgenic Animals and Plants 432 11.13 Antibiotics Drug Resistance 433 11.14 Regulatory Issues 435 11.15 Intellectual Property Rights and Marketing Exclusivities 437 11.16 Bioethics 440 11.17 Concluding Remarks 442 11.18 Case Study #11.1 445 11.19 Case Study #11.2 447 11.20 Further Reading 449 APPENDIX 1 HISTORY OF DRUG DISCOVERY AND DEVELOPMENT 451 A1.1 Early History of Medicine 451 A1.2 Drug Discovery and Development in the Middle Ages 453 A1.3 Foundation of Current Drug Discovery and Development 454 A1.4 Beginnings of Modern Pharmaceutical Industry 454 A1.5 Evolution of Drug Products 455 A1.6 Further Reading 456 APPENDIX 2 CELLS, NUCLEIC ACIDS, GENES, AND PROTEINS 457 A2.1 Cells 457 A2.2 Nucleic Acids 460 A2.3 Genes and Proteins 462 A2.4 Further Reading 468 APPENDIX 3 SELECTED DRUGS AND THEIR MECHANISMS OF ACTION 469 APPENDIX 4 A DHFR PLASMID VECTOR 481 APPENDIX 5 VACCINE PRODUCTION METHODS 483 APPENDIX 6 VACCINES APPROVED BY FDA 485 APPENDIX 7 PHARMACOLOGY/TOXICOLOGY REVIEW FORMAT 489 APPENDIX 8 EXAMPLES OF GENERAL BIOMARKERS 495 APPENDIX 9 TOXICITY GRADING 499 APPENDIX 10 HEALTH SYSTEMS IN SELECTED COUNTRIES 505 ACRONYMS 509 GLOSSARY 515 INDEX 519.
• (source: Nielsen Book Data)9781118907276 20160802

The third edition of this best-selling book continues to offer a user-friendly, step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of pre-clinical studies, the conduct of human clinical trials, regulatory controls, and even the manufacturing processes for pharmaceutical products. Concise and easy to read, Drugs: From Discovery to Approval, Third Edition quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs. The third edition incorporates the latest developments and updates in the pharmaceutical community, provides more comprehensive coverage of topics, and includes more materials and case studies suited to college and university use. Biotechnology is a dynamic field with changes across R&D, clinical trials, manufacturing and regulatory processes, and the third edition of the text provides timely updates for those in this rapidly growing field.
(source: Nielsen Book Data)9781118907276 20160802

• Introduction: The Five Ws of Pharmaceutical Green Chemistry-- Barriers to Adopting Green Chemistry in Drug Discovery-- Toward a Green Laboratory: One Reaction at a Time-- Greener Solvent Usage for-- Discovery Chemistry Analysis and Purification-- Green Chemistry and High Throughput Screening-- Continuous Processing in Drug Discovery-- Applying Green Chemistry Principles in Biologics Drug Development-- Recycling and Reuse in the Laboratory-- The Need for a Green Electronic Lab Notebook-- Toxicology for Chemical Safety and Sustainability-- Environmental Regulations and the Green Chemist-- Patent Protection and Green Chemistry Innovation-- The Business Case for Green Chemistry in Drug Discovery.
• (source: Nielsen Book Data)9781849739610 20160619

The incorporation of Green Chemistry is a relatively new phenomenon in the drug discovery discipline, since the scale that chemists operate on in drug discovery is smaller than those of process and manufacturing chemistry. The necessary metrics are more difficult to obtain in drug discovery due to the diversity of reactions conducted. However, pharmaceutical companies are realizing that incorporation of green chemistry techniques at earlier stages of drug development can speed the development of a drug candidate. Written by experts who have pioneered green chemistry efforts within their own institutions, this book provides a practical guide for both academic and industrial labs wanting to know where to start with introducing greener approaches for greatest return on investment. The Editors have taken a comprehensive approach to the topic, covering the entire drug discovery process from molecule conception, through synthesis, formulation and toxicology with specific examples and case studies where green chemistry strategies have been implemented. Emerging techniques for performing greener drug discovery chemistry are addressed as well as cutting-edge topics like biologics discovery and continuous processing. Moreover, important surrounding issues such as intellectual property are included. This book serves as a practical guide for both academic and industrial chemists who work across the breadth of the drug discovery discipline. Ultimately, readers will learn how to incorporate green chemistry strategies into their everyday workflow without slowing down their science.
(source: Nielsen Book Data)9781849739610 20160619

• Introduction-- Library design-- Physicochemical properties and drug design-- Computational chemistry-- Structure-based drug design-- Fragment based design-- QSAR-- Drug metabolism-- Pharmacokinetics-- Molecular biology-- Computational biology-- In vitro-- In vivo-- Translational science-- Assays-- Toxicology-- Intellectual property-- Modern drug design-- Lead generation-- Lead optimisation-- Predictive toxicology-- Pharmaceutical development-- Process research-- Project management-- Clinical development-- Case Study 1-- Case Study 2-- Case Study 3.
• (source: Nielsen Book Data)9781849736251 20160618

Drug discovery is a constantly developing and expanding area of research. Developed to provide a comprehensive guide, the Handbook of Medicinal Chemistry covers the past, present and future of the entire drug development process. Highlighting the recent successes and failures in drug discovery, the book helps readers to understand the factors governing modern drug discovery from the initial concept through to a marketed medicine. With chapters covering a wide range of topics from drug discovery processes and optimization, development of synthetic routes, pharmaceutical properties and computational biology, the handbook aims to enable medicinal chemists to apply their academic understanding to every aspect of drug discovery. Each chapter includes expert advice to not only provide a rigorous understanding of the principles being discussed, but to provide useful hints and tips gained from within the pharmaceutical industry. This expertise, combined with project case studies, highlighting and discussing all areas of successful projects, make this an essential handbook for all those involved in pharmaceutical development. A free app has been created in collaboration with the editors of the book. The Medicinal Chemistry Toolkit provides a suite of resources to support the day to day work of a medicinal chemist. Search the App store for "Medicinal Chemistry Toolkit.".
(source: Nielsen Book Data)9781849736251 20160618

• Preface-- Chanelling drug discovery-- Chanome old and new-- High throughput screening-- Automated electrophysiology-- Structure/crystallization/modeling studies-- Toxins - does nature do ion channel drug discovery better than us? Structure and function of Sodium Channels, pharmacophores and binding sites-- AMPA modulators - a case history-- Inhibition of the epithelial sodium channel (ENaC) as a therapeutic approach to respiratory disease-- CFTR channel modulation as a therapeutic approach-- TRPs are a pain: a case history on TRPV1 antagonist development-- The Retigabine story - the M current to therapeutically useful anticonvulsant-- Icrac and Orai - a STIMulating channel-- hERG past, present and future? Antibodies as ion channel modulators-- Summary and the future-- Index.
• (source: Nielsen Book Data)9781849735087 20160616

Ion channel drug discovery is a rapidly evolving field fuelled by recent, but significant, advances in our understanding of ion channel function combined with enabling technologies such as automated electrophysiology. The resurgent interest in this target class by both pharmaceutical and academic scientists was clearly highlighted by the over-subscribed RSC/BPS 'Ion Channels as Therapeutic Targets' symposium in February 2009. This book builds on the platform created by that meeting, covering themes including advances in screening technology, ion channel structure and modelling and up-to-date case histories of the discovery of modulators of a range of channels, both voltage-gated and non-voltage-gated channels. The editors have built an extensive network of contacts in the field through their first-hand scientific experience, collaborations and conference participation and the organisation of the meeting at Novartis, Horsham, increased the network enabling the editors to draw on the experience of eminent researchers in the field. Interest and investment in ion channel modulation in both industrial and academic settings continues to grow as new therapeutic opportunities are identified and realised for ion channel modulation. This book provides a reference text by covering a combination of recent advances in the field, from technological and medicinal chemistry perspectives, as well as providing an introduction to the new 'ion channel drug discoverer'. The book has contributions from highly respected academic researchers, industrial researchers at the cutting edge of drug discovery and experts in enabling technology. This combination provides a complete picture of the field of interest to a wide range of readers.
(source: Nielsen Book Data)9781849735087 20160616